A study in the management of anxiety with lorazepam

A four-week double-blind comparison between lorazepam and placebo involving 60 patients with anxiety revealed that lorazepam in a mean dose of approximately 3 mg on a b.i.d. regimen is significantly and clinically more effective than placebo for almost all items of the Global, Hamilton, and 35-Item...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical pharmacology Vol. 18; no. 4; p. 210
Main Authors Ellison, Jr, R J, Cancellaro, L A
Format Journal Article
LanguageEnglish
Published England 01.04.1978
Subjects
Adult
Anti-Anxiety Agents - therapeutic use
Anxiety - drug therapy
Clinical Trials as Topic
Female
Humans
Lorazepam - administration & dosage
Lorazepam - therapeutic use
Male
Middle Aged
Placebos
Psychiatric Status Rating Scales
Online AccessGet more information

Cover

More Information
Summary:A four-week double-blind comparison between lorazepam and placebo involving 60 patients with anxiety revealed that lorazepam in a mean dose of approximately 3 mg on a b.i.d. regimen is significantly and clinically more effective than placebo for almost all items of the Global, Hamilton, and 35-Item scales at nearly all evaluation periods. Moreover, lorazapem was associated with a 50% greater improvement rate than was placebo. Except for only one patient who was withdrawn from the study because of severe sedation, lorazepam was well tolerated and did not interact adversely with concomitant nonpsychoactive medication.
ISSN:0091-2700
DOI:10.1002/j.1552-4604.1978.tb01595.x